A 52-year-old man with newly diagnosed hypertension and type 2 diabetes mellitus presents for antihypertensive therapy initiation. He has no proteinuria, normal renal function, and no prior cardiovascular events. Which drug is the first-line choice for this patient?

Explanation

## First-Line Antihypertensive in Hypertension with Diabetes **Key Point:** ACE inhibitors (or ARBs) are the first-line agents for hypertension in patients with diabetes mellitus, regardless of the presence of albuminuria or proteinuria. ### Mechanism of Benefit in Diabetes 1. **Renal protection:** ACE inhibitors reduce intraglomerular pressure by preferentially dilating the efferent arteriole, slowing diabetic nephropathy progression. 2. **Cardiovascular protection:** Reduce left ventricular hypertrophy and have anti-atherosclerotic effects. 3. **Metabolic neutrality:** Do not adversely affect glucose metabolism (unlike thiazides and beta-blockers). ### Evidence Base | Feature | ACE Inhibitor | Calcium Channel Blocker | Thiazide | Beta-Blocker | | --- | --- | --- | --- | --- | | **Renal protection in DM** | ✓ (proven) | ✗ | ✗ | ✗ | | **CV mortality reduction** | ✓ | ✓ | ✗ | ✓ (limited) | | **Metabolic effects** | Neutral | Neutral | Adverse (↑ glucose) | Adverse (↓ awareness) | | **First-line in DM + HTN** | **Yes** | No | No | No | **High-Yield:** The 2017 ACC/AHA Guidelines and Indian hypertension guidelines recommend ACE-I/ARB as first-line for all hypertensive patients with diabetes, with or without albuminuria. **Clinical Pearl:** Lisinopril (or any ACE inhibitor) should be initiated at a low dose (e.g., 10 mg daily) and titrated based on response and tolerability. Monitor K^+^ and creatinine at baseline and 1–2 weeks after initiation. ### Why Lisinopril is Superior Here - Proven reduction in diabetic nephropathy progression - Reduces cardiovascular events in diabetic patients - No adverse metabolic effects - Cost-effective and well-tolerated [cite:Harrison 21e Ch 297]